Stoke Therapeutics, Inc. (STOK) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.
Key numbers for Stoke Therapeutics, Inc. (STOK): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.
AllSight quality score: 38/100 — a percentile rank of Stoke Therapeutics, Inc.’s fundamentals against Manufacturing peers, weakest on management. A quality ranking, not a price prediction.
| Market cap | $1.7B |
| P / S | 60.8× |
| EV / EBITDA | -7.1× |
| Gross margin | 100.0% |
| Operating margin | -809.7% |
| Net margin | -753.6% |
| Return on equity | -60.2% |
| ROIC | -94.3% |
| Revenue growth | -86.2% |
| Debt / equity | 0.0× |
| Dividend yield | 0.0% |
Is Stoke Therapeutics, Inc. overvalued? P/S looks overvalued vs its 5-year range; P/B looks overvalued vs its 5-year range.
Independent of the events above — derived from Stoke Therapeutics, Inc.’s own financial statements and shown as context, never as advice.
About AllSight · Editorial standards & method · Contact